Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately seven years earlier than the expiration of the Warner Chilcott patent at issue in the litigation, or earlier in certain circumstances.
Barr will pay Warner Chilcott a royalty on net sales of Barr’s generic product. The parties said that the filing of a dismissal without prejudice in the US District Court of New Jersey concludes this litigation.